← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-11 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleRochePhase 3

Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C (Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C)

B-cell Non Hodgkin Lymphoma; Mature B-cell Leukemia Burkitt-type · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Rituximab, lenalidomide (Rituximab, lenalidomide)

Primary CNS Lymphoma · Primary CNS Lymphoma

#PrimaryCNSLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Rituximab-CHOP-Alemtuzumab (Rituximab-CHOP-Alemtuzumab)

Chronic Lymphocytic Leukaemia; Patients Resistant to a Purine Analogous · Chronic Lymphocytic Leukaemia

#ChronicLymphocyticLeukaemia#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleRochePreclinical

Rituximab-EU+ Rituximab-Pfizer x 2 Courses (Rituximab-EU+ Rituximab-Pfizer x 2 Courses)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

RMTT (Rituximab-Methotrexate-Temozolomide-Thiotepa, Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT))

Primary Central Nervous System Lymphoma · Primary Central Nervous System Lymphoma

#PrimaryCentralNervousSystemLymph#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePreclinical

Rituximab-Pfizer (PF-05280586, Rituximab-Pfizer, Rituximab-Pfizer (PF-05280586) x 3 courses)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

Rituximab-US + Rituximab-Pfizer x 2 Courses (Rituximab-US + Rituximab-Pfizer x 2 Courses)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAmgenPhase 3

Romosozumab (Romosozumab)

Postmenopausal Osteoporosis · Postmenopausal Osteoporosis

#PostmenopausalOsteoporosis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Rucaparib and Nivolumab)

Small Cell Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 4%임상시험 1상태 ACTIVE
AntibodystaleAmsterdam UMC, location VUmcPhase 2

pembrolizumab (Keytruda, SABR + pembrolizumab)

NSCLC, Stage I · NSCLC, Stage I

#NSCLCStageI#Antibody#Phase2#항체#면역항체+4
효능 ORR 41%임상시험 1상태 ACTIVE
AntibodystaleSanofiPhase 2

Tusamitamab ravtansine (SAR408701, SAR408701 (Tusamitamab ravtansine))

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) · Non-squamous Non-small-cell Lung Cancer

#Non-squamousNon-small-cellLungCa#Antibody#Phase2#항체#면역항체+2
효능 ORR 66.7%임상시험 1상태 DISCONTINUED
AntibodystaleSamsung Bioepis Co., Ltd.Phase 3

proposed biosimilar to infliximab (SB2, SB2 (proposed biosimilar to infliximab))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

proposed trastuzumab biosimilar (SB3, SB3 (proposed trastuzumab biosimilar))

Breast Neoplasms · HER2

#HER2#Antibody#Preclinical#항체#면역항체+3
효능 ORR 91.2%임상시험 1상태 DISCONTINUED
AntibodystaleSamsung Bioepis Co., Ltd.Approved

Adalimumab Biosimilar (SB5, SB5 (Adalimumab Biosimilar))

Plaque Psoriasis · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Approved#항체#면역항체+2
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleAbbViePhase 3

proposed biosimilar to adalimumab (SB5, SB5 (proposed biosimilar to adalimumab))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleInstitut Cancerologie de l'OuestPhase 2

durvalumab (Imfinzi, SBRT + Durvalumab)

Node; Prostate; Bone Metastases · Node; Prostate

#NodeProstate#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 RECRUITING
AntibodystaleAbramson Cancer Center at Penn …Phase 1

atezolizumab (Tecentriq, SBRT + atezolizumab and bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

SC0191 + Bevacizumab (SC0191 + Bevacizumab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJanssenApproved

daratumumab (Darzalex, SCT800 and Daratumumab)

Hemophilia A With Inhibitor · Hemophilia A With Inhibitor

#HemophiliaAWithInhibitor#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING

70 / 92 페이지

← 이전다음 →